Slovenia's Lek Calls Highest Bidder
Executive Summary
Novartis' €823 million ($812 million) offer for Slovenia's second largest drug firm looks generous and would give Lek a strong US and EU distribution channel. But Lek's key shareholders think the company can command an even higher price.
You may also be interested in...
Radiopharmaceuticals: A New Frontier In Precision Cancer Therapy
Growing interest in radioligand-based cancer therapies reflects the class’s unique advantages – including the ability to “see what you treat.”
The New Antibodies Revolutionizing Medicine
Nucleic acid-based therapies are poised to revolutionize medicine – just as antibodies did thirty years ago.
What Next In Oncology?
Oncology dominates pharma sales and pipeline league tables. But where is the next Keytruda?